Newly identified enzyme treats deadly bacterial infections in mice

Jul 02, 2008

By the time antibiotics made their clinical debut 70 years ago, bacteria had long evolved strategies to shield themselves. For billions of years, bacteria hurled toxic molecules at each other in the struggle to prosper, and those that withstood the chemical onslaught marched on. Now, with an uptick in antibiotic-resistant bacteria reaching alarming proportions, Rockefeller University scientists have identified an enzyme produced in viruses (called bacteriophages) that could stop these one-celled powerhouses dead in their tracks.

In research published this month in The Journal of Infectious Diseases, scientists led by Vincent Fischetti, head of the Laboratory of Bacterial Pathogenesis and Immunology, reveal that the newly identified enzyme, Cpl-1, can successfully treat symptoms of bacterial meningitis in young mice infected with Streptococcus pneumoniae, a highly resistant and deadly strain of bacteria. At a time when antibiotics have continued to prove futile, these findings may provide a solution to one of the more serious public health problems to hit this century.

“We have reached another critical milestone,” says Fischetti, who previously showed that Cpl-1 prevents ear infections in mice. “To argue that these enzymes can be clinically effective, we had to prove that they not only kill antibiotic-resistant bacteria but also reverse their symptoms of disease. And that’s what we did.”

Working with colleagues from the Institute for Infectious Diseases in Bern, Switzerland, Fischetti found that young mice infected with S. pneumoniae and then treated 18 hours later, once symptoms began, survived the potentially deadly infection. Moreover, Cpl-1 destroyed all traces of the most resistant and virulent strains of S. pneumoniae. In a test tube, this eradication took seconds; in the animal, it took a mere four hours and without collateral damage, suggesting that in mice, Cpl-1 is both a selective and safe treatment for drug-resistant bacterial meningitis.

Unlike the guerrilla warfare tactics of antibiotics, which give bacteria time to assemble their resources and develop resistance, phage enzymes strike with blitzkrieg speed and surprise, preventing bacteria from organizing a coherent defense. Without an effective strategy to fight them, bacteria are faced with a war they may not be able to win.

“We have had nothing to control these invasive diseases,” says Fischetti. “This approach may finally give us something.”

Citation: The Journal of Infectious Diseases 197(11): 1519–1522 (June 1, 2008)

Source: Rockefeller University

Explore further: France to receive first Ebola patient

add to favorites email to friend print save as pdf

Related Stories

Foiling bugs that foil drugs

Aug 12, 2014

Every week, faculty members in the department of chemistry meet over lunch to discuss current literature in the field. The conversation at one of these meetings led Marcos Pires to what he calls a "crazy ...

An easier way to manipulate malaria genes

Aug 11, 2014

Plasmodium falciparum, the parasite that causes malaria, has proven notoriously resistant to scientists' efforts to study its genetics. It can take up to a year to determine the function of a single gene, ...

Sharpening a test for tracing food-borne illness to source

Jun 23, 2014

Research from the University of Melbourne, Australia, could make it easier for public health investigators to determine if a case of food poisoning is an isolated incident or part of a larger outbreak. The findings are published ...

Research team implants human innate immune cells in mice

Mar 18, 2014

(Phys.org) —Overcoming a major limitation to the study of the origins and progress of human disease, Yale researchers report that they have transplanted human innate immune cells into mouse models, which ...

Recommended for you

France to receive first Ebola patient

5 minutes ago

France on Wednesday prepared to receive its first Ebola patient, as the World Bank warned the spiralling epidemic is threatening economic catastrophe in west Africa.

US scientist: Ebola unlikely to become airborne

1 hour ago

It is unlikely that Ebola would mutate to spread through the air, and the best way to make sure it doesn't is to stop the epidemic, a top U.S. government scientist told concerned lawmakers Wednesday.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

menkaur
not rated yet Jul 02, 2008
yeah... and then there will be enzyme resistance ... you've got to use the medications in a right way and to control it - meaning - no selling it in shops etc...